Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17927906 | 0.81 | HDAC1 (0.56) | HDAC1HDAC6ITGB1ITGA4POLB | |
| SCHEMBL12650529 | 0.80 | HMOX1 (0.56) | HMOX1HDAC6MMP12KEAP1FFAR1 | |
| SCHEMBL1776201 | 0.78 | HMOX1 (0.54) | HMOX1KEAP1HSD11B1POLBTDP1 | |
| SCHEMBL14736671 | 0.78 | HDAC1 (0.53) | HDAC1HDAC6POLB | |
| SCHEMBL1775577 | 0.77 | HMOX1 (0.53) | HMOX1KEAP1FFAR1HSD11B1POLB | |
| SCHEMBL9996085 | 0.77 | POLB (0.64) | HMOX1POLBL3MBTL1 | |
| SCHEMBL1776247 | 0.76 | HMOX1 (0.52) | HMOX1 | |
| SCHEMBL410721 | 0.76 | HPGD (0.62) | HMOX1HDAC6POLBL3MBTL1 | |
| SCHEMBL11604895 | 0.75 | HDAC1 (0.53) | HDAC1HDAC6ITGB1ITGA4DGAT1 | |
| SCHEMBL1774841 | 0.74 | TSHR (0.59) | HMOX1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | claimed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | claimed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-8632914-B2 | Triazolium and imidazolium salts and uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-20 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| WO-2010025558-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF AS ANTIMALARIALS | UNIVERSITY HAEALTH NETWORK (CA) | 2010-03-11 | — | — | WO | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | HMOX1 2/4885HDAC1 867/4885HDAC6 1454/4885 |
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | ARG2, ARG1, CIT | HMOX1 3276/4885HDAC1 1018/4885HDAC6 758/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HMOX1 1/4885HDAC1 953/4885HDAC6 994/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HMOX1 1/4885HDAC1 953/4885HDAC6 994/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HMOX1 1/4885HDAC1 886/4885HDAC6 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.